Skip to content

Anti Gm1 Igg Antibody Positivity C5676708

Published: July 22, 2026Updated: August 20, 2026

Anti-GM1 IgG antibody positivity involves IgG antibodies targeting GM1 gangliosides on nerves. This can be associated with autoimmune neuropathy causing weakness and sensory disturbances. Treatment typically requires immunotherapy and depends on the underlying condition.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
G43.909
ICD-11
8A00.0
Body system
neurologic
Severity
severe
Chronic
false

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Warning signs - seek immediate care

!

Ascending symmetric weakness

!

Respiratory failure requiring mechanical ventilation

Generalized symptoms

(neurologic)

Significant symptoms that substantially affect daily functioning.

Frequency: Varies

Paresthesia of extremities

(neurologic)

Facial weakness

(neurologic)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Intravenous Immunoglobulin (IVIG)

IVIG provides immunomodulation by blocking Fc receptors, inhibiting complement binding, and neutralizing pathogenic IgG antibodies targeting gangliosides.

medication
2

Targeted drug therapy with dose adjustment

Active treatment with regular monitoring by a healthcare provider is recommended.

medication
3

Therapeutic Plasma Exchange

Mechanical removal of circulating IgG anti-GM1 antibodies and replacement with albumin or plasma, reducing autoimmune attack on nerve tissue.

procedure

Additional treatment options

Immunosuppressive Therapy

Second-line agents such as cyclophosphamide or rituximab target B-cell function to reduce ongoing antibody production.

medication

Electrotherapy and Neuromuscular Rehabilitation

Electrical stimulation and targeted exercises promote nerve regeneration and prevent muscle atrophy during recovery phase.

physical_therapy

Neurophysiological Follow-up

Serial nerve conduction studies and EMG to objectively track nerve function recovery and treatment efficacy over time.

monitoring

When to seek medical help

Recognize when you need immediate medical attention.

See a doctor within 24 hours

Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.

Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Anti Gm1 Igg Antibody Positivity C5676708?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

van den Bergh PYK, Piéret F, Rajabally YA. Consensus on the management of immune-mediated neuropathies: Guidelines from the Peripheral Nerve Society. Neurology. 2021.

guideline2021
2

Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome and anti-ganglioside antibodies: Clinical and immunological perspectives. Lancet Neurol. 2022.

review2022
3

Kuwabara S, Misawa S, Mori M. Anti-GM1 antibody titers and clinical outcomes in acute motor axonal neuropathy: A prospective cohort study. J Neurol Neurosurg Psychiatry. 2020.

clinical_trial2020
4

Shahrizaila N, Yuki N. Association between anti-ganglioside antibodies and neurological outcomes in autoimmune neuropathies: Systematic review and meta-analysis. Muscle Nerve. 2023.

meta_analysis2023

Medication Comparisons

Compare medications used to treat Anti Gm1 Igg Antibody Positivity C5676708. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy